Tests valbenazine in adults with tardive dyskinesia who still have symptoms
Tests valbenazine in adults with tardive dyskinesia still symptomatic on prior treatment.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Key facts
- Where
- Augusta, Austin, Bonita Springs, Bryant, Chino, Fresno, Hialeah, Independence, Long Beach, Miami, Naperville, Omaha, Orange, Orange City, Port Charlotte, Redlands, Richmond, San Diego, and Tampa, United StatesSee the 19 sites
- Phase
- Phase 4
Where in United States
- AugustaAugusta, United StatesTaking people
- AustinAustin, United StatesTaking people
- Bonita SpringsBonita Springs, United StatesTaking people
- BryantBryant, United StatesTaking people
- ChinoChino, United StatesTaking people
- FresnoFresno, United StatesTaking people
- HialeahHialeah, United StatesTaking people
- IndependenceIndependence, United StatesTaking people
- Long BeachLong Beach, United StatesTaking people
- MiamiMiami, United StatesTaking people
- NapervilleNaperville, United StatesTaking people
- OmahaOmaha, United StatesTaking people
- OrangeOrange, United StatesTaking people
- Orange CityOrange City, United StatesTaking people
- Port CharlottePort Charlotte, United StatesTaking people
- RedlandsRedlands, United StatesTaking people
- RichmondRichmond, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- TampaTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neurocrine Biosciences
- Trial code
- NCT07105111
- Record updated
- 18 September 2026
- Original description
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.Read full original descriptionShow less
A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
Inclusion: 18 years of age or older; Diagnosed with one of the following at least 3 months prior to screening: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder; Diagnosed with at least mild neuroleptic-induced TD for at least 3 months prior to screening.
Exclusion: Diagnosis of moderate or severe substance use disorder in the last 6 months; History of long QT syndrome, cardiac arrythmia, or severe hepatic impairment; Have comorbid Parkinsonism or abnormal involuntary movement(s) that is more prominent than TD.